Objective To investigate the value of DNA-image cyt-ometry (DNA-ICM) in the diagnosis of urothelial cell carcinomas (UCC). Methods Totally 162 voided urine specimens (92 cases from urothel-ial car-cinomas patients and 70 cases from benign urinary system diseases patients ) were detected with DNA-ICM and liquid-based cytology (LBC), respectively. Results The sensitivity and specificity of DNA-ICM were 65.2%and 100% respectively in the diagnosis of UCC but those of LBC were 27.2% and 98.6%, respectively. The sensitivity of DNA-ICM was significantly higher than that of LBC in the diagnosis of UCC (P < 0.01). The sen-sitivity of DNA-ICM in upper urinary tract urothelial cell carcinomas (UTUC) were 77.1%, which was much higher than that in bladder urothelial cell carcinomas (57.9%) but no statistical significance was found (P >0.01). Conclusion DNA-ICM, which improves the positive rate of urinary cytology, has great application value in the diagnosis of urothelial cell carcinomas and it is an effective screening method for urothelial cancer in diag-nosis and follow-up.

【Objective:】 To understand the current situation of nurses’ professional quality of life in China and its correlation with benefit findings, so as to provide reference for formulating targeted measures to improve nurses’ professional quality of life in China. 【Methods:】 Questionnaire star was used to conduct a cross-sectional survey of 11 924 registered nurses in China from January 2022 to April 2022 using the General Information Questionnaire, the Professional Quality of Life Scale (ProQOL) and the General Benefit Discovery Scale (GBFS). SPSS 22.0 software was used for data analysis. 【Results:】 The scores of various dimensions of nurses’ ProQOL scale were: compassion satisfaction was (32.71±6.81) points, burnout was (27.38±5.20) points, secondary traumatic stress was (28.44±6.67) points, and the total score of GBFS was (100.90±18.04) points. The results of multiple linear stepwise regression showed that the main influencing factors of compassion satisfaction were marital status, position, work unit level and educational background (P<0.05). The main influencing factors of burnout were position, professional title, work unit level and whether there were children to be taken care of at home (P<0.05). The main influencing factors of secondary traumatic stress were education background, marital status, professional title, whether there was an old person to be taken care of at home, whether to take care of COVID-19 patients, whether to be an epidemic support staff and position (P<0.05). Benefit finding independently predicted the three dimensions of nurses’ professional quality of life (P<0.001). 【Conclusions:】 Chinese nurses’ professional quality of life was at a moderate level and it was significantly affected by benefit finding. Attention should be paid to factors such as marital status, work unit level, position, professional title, education background, whether there was an old person to be taken care of at home, whether to take care of COVID-19 patients, so as to improve the level of nurses’ benefit finding, promote their personal growth, provide good job guarantee, and improve Chinese nurses’ professional quality of life.

To know the current status of family health and negative psychology of primary and secondary school students, and to explore the correlation between them during the prevention and control of COVID-19. From January 15 to 30, in 2022, a total of 19 343 urban and rural primary and secondary school students in X city were selected. The short form of the family health scale, center for epidemiologica survey-depression scale and student burnout inventory for junior middle school students were used to conduct a cross-sectional survey. The Pearson correlation was used to analyze the relationship between the family health and negative psychology. The family health of primary and secondary school students is at the medium level or above, and more than half of students may/must be depressed. There are significant differences in study burnout in different learning stages and epidemic management in different places of residence. It is recommended that family members and schools staff should give more psychological and social support to primary and secondary school students to reduce the negative impact of COVID-19 on them.

BACKGROUND: LY01005 (Goserelin acetate sustained-release microsphere injection) is a modified gonadotropin-releasing hormone (GnRH) agonist injected monthly. This phase III trial study aimed to evaluated the efficacy and safety of LY01005 in Chinese patients with prostate cancer. METHODS: We conducted a randomized controlled, open-label, non-inferiority trial across 49 sites in China. This study included 290 patients with prostate cancer who received either LY01005 or goserelin implants every 28 days for three injections. The primary efficacy endpoints were the percentage of patients with testosterone suppression ≤50 ng/dL at day 29 and the cumulative probability of testosterone ≤50 ng/dL from day 29 to 85. Non-inferiority was prespecified at a margin of -10%. Secondary endpoints included significant castration (≤20 ng/dL), testosterone surge within 72 h following repeated dosing, and changes in luteinizing hormone, follicle-stimulating hormone, and prostate specific antigen levels. RESULTS: On day 29, in the LY01005 and goserelin implant groups, testosterone concentrations fell below medical-castration levels in 99.3% (142/143) and 100% (140/140) of patients, respectively, with a difference of -0.7% (95% confidence interval [CI], -3.9% to 2.0%) between the two groups. The cumulative probabilities of maintaining castration from days 29 to 85 were 99.3% and 97.8%, respectively, with a between-group difference of 1.5% (95% CI, -1.3% to 4.4%). Both results met the criterion for non-inferiority. Secondary endpoints were similar between groups. Both treatments were well-tolerated. LY01005 was associated with fewer injection-site reactions than the goserelin implant (0% vs . 1.4% [2/145]). CONCLUSION: LY01005 is as effective as goserelin implants in reducing testosterone to castration levels, with a similar safety profile. TRIAL REGISTRATION ClinicalTrials.gov, NCT04563936.
Humans ; Male ; Antineoplastic Agents, Hormonal/therapeutic use* ; East Asian People ; Gonadotropin-Releasing Hormone/agonists* ; Goserelin/therapeutic use* ; Prostate-Specific Antigen ; Prostatic Neoplasms/drug therapy* ; Testosterone